Role of CSF-1 in progression of epithelial ovarian cancer

被引：21

作者：

Chambers, Setsuko K. ^{[1
]}

机构：

[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA

来源：

FUTURE ONCOLOGY | 2009年 / 5卷 / 09期

关键词：

c-fms proto-oncogene; CSF-1; epithelial ovarian cancer; HuR; invasion; metastasis; post-transcriptional; regulation; urokinase; COLONY-STIMULATING FACTOR; C-FMS PROTOONCOGENE; 3' UNTRANSLATED REGION; POOR PROGNOSTIC-FACTOR; FACTOR MESSENGER-RNA; FACTOR-I CSF-1; INDUCED MONOCYTIC DIFFERENTIATION; ARACHIDONIC-ACID METABOLITES; CYTOPLASMIC HUR EXPRESSION; TUMOR-NECROSIS-FACTOR;

D O I：

10.2217/FON.09.103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and metastasis of ovarian cancer is key to development of targeted therapeutics. It is only in this way that therapeutic potential can be translated to reality. Here, we describe the evidence to date for the role of CSF-1/c-fms signaling in ovarian cancer invasiveness and metastasis, including the recent understanding of how CSF-1/c-fms expression is regulated with identification of significant post-transcriptional regulators.

引用

页码：1429 / 1440

页数：12

共 127 条

[1] Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice [J].

Aharinejad, S ;

Paulus, P ;

Sioud, M ;

Hofmann, M ;

Zins, K ;

Schäfer, R ;

Stanley, ER ;

Abraham, D .

CANCER RESEARCH, 2004, 64 (15) :5378-5384

[2]

Aharinejad S, 2002, CANCER RES, V62, P5317

[3] Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) [J].

Alberts, D. S. ;

Liu, P. Y. ;

Wilczynski, S. P. ;

Jang, A. ;

Moon, J. ;

Ward, J. H. ;

Beck, J. T. ;

Clouser, M. ;

Markman, M. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (04) :784-788

[4] TEMPORAL EXPRESSION AND LOCATION OF COLONY-STIMULATING FACTOR-I (CSF-1) AND ITS RECEPTOR IN THE FEMALE REPRODUCTIVE-TRACT ARE CONSISTENT WITH CSF-1-REGULATED PLACENTAL DEVELOPMENT [J].

ARCECI, RJ ;

SHANAHAN, F ;

STANLEY, ER ;

POLLARD, JW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8818-8822

[5]

BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO

[6]

2-8

[7] Binding proteins for mRNA localization and local translation, and their dysfunction in genetic neurological disease [J].

Bassell, GJ ;

Kelic, S .

CURRENT OPINION IN NEUROBIOLOGY, 2004, 14 (05) :574-581

[8] Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer:: A phase I trial [J].

Berkenblit, A ;

Matulonis, UA ;

Kroener, JF ;

Dezube, BJ ;

Lam, GN ;

Cuasay, LC ;

Brünner, N ;

Jones, TR ;

Silverman, MH ;

Gold, MA .

GYNECOLOGIC ONCOLOGY, 2005, 99 (01) :50-57

[9] Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-rich 3′ untranslated region of colony-stimulating factor-1 (CSF-1) messenger RNA in human ovarian cancer cells:: Possible role in CSF-1 posttranscriptional regulation and tumor phenotype [J].

Bonafé, N ;

Gilmore-Hebert, M ;

Folk, NL ;

Azodi, M ;

Zhou, Y ;

Chambers, SK .

CANCER RESEARCH, 2005, 65 (09) :3762-3771

[10] ISOLATION AND CHARACTERIZATION OF A CDNA CLONE ENCODING FOR RAT CSF-1 GENE - POSTTRANSCRIPTIONAL REPRESSION OCCURS IN MYOGENIC DIFFERENTIATION [J].

BORYCKI, AG ;

LENORMAND, JL ;

GUILLIER, M ;

LEIBOVITCH, SA .

BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1174 (02) :143-152

← 1 2 3 4 5 6 7 8 9 10 →